The cardiovascular diseases (CVDs) therapeutic drugs are used to treat several disorders of the heart and blood vessels such as coronary artery disease, arrhythmias, and heart defects, among others.
The Cardiovascular Therapeutic Drugs market growth is driven by rising prevalence of cardiovascular diseases globally, growing elderly population, and increasing development of new drugs for the treatment of CVDs.
According to the World Health Organization (WHO), in 2017, CVD is the number 1 cause of death globally. In 2016, an estimated 17.9 million people died from CVDs, representing 31% of all global deaths. Of these deaths, 85% are due to heart attack and stroke.
However, high investment cost and recent expiry of patent exclusivity of cardiovascular drugs are some of the factors hampering the growth of the Cardiovascular Drugs Market. For instance, in July 2015, Novartis set a price of $4,560 a year for its new heart failure pill Entresto, nearly 50% higher than expected.
By drug class, the Cardiovascular Therapeutic Drugs Market is segmented into Anti hyperlipidemias, Anti-hypertensives, Anti-coagulants, Anti-fibrinolytics, Anti-arrhythmic, and Others. Among these, anti-coagulants drug class is projected to account for the largest market share during the forecast period, followed by anti-hyperlipidemia segment.
On the basis of diseases, the market is segmented into cardiac arrhythmias, hypertension, arteriosclerosis, acute coronary syndrome, myocardial infarction, peripheral artery disease, coronary artery disease, cardiac failure diseases, thrombosis, hyperlipidemia, and others.
North America is dominating the Cardiovascular Therapeutic Drugs market in 2018 and estimated to hold largest market size over the forecast period (2019-2026), owing to the rising prevalence of cardiovascular disease and introduction of new drugs for the treatment. Cardiovascular disease (CVD), is one of the major cause of death, accounted for 840,678 deaths in the US in 2016, approx. 1 of every 3 deaths. Between 2013 and 2016, 121.5 million American adults had some form of cardiovascular disease. As per the American Heart Association, 2019, 116.4 million or 46% of the US adults are estimated to have hypertension.
The Cardiovascular Therapeutic Drugs market is dominated by few major players including Biophan Technologies, Berlin Heart GmbH, Calon Cardio-Technology Ltd., MAQUET GmbH & Co., Teleflex Incorporated, Heart Ware International, Abiomed Inc., Thoratec Corporation, SynCardia Systems, and Bioheart.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
